| abstract |
The present invention is a cancer antigen-specific chimeric antigen receptor comprising a FLT3-specific monoclonal antibody or a functional fragment thereof, a transmembrane domain, and a CD3ΞΆ domain of a T cell receptor for more efficient immunotherapy of acute myelogenous leukemia. , CAR) Transformed host immune cells to express a protein, a genetically modified NK cell line and uses thereof are provided. |